Gaylis N[au] - Search Results

Year	Number of Results
1981	1
1982	2
1986	1
2003	1
2007	2
2009	2
2010	1
2011	2
2012	3
2013	2
2014	2
2015	2
2017	1
2019	1
2020	1
2021	2
2022	2

1

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU; GO-AFTER study investigators. Smolen JS, et al. Among authors: gaylis n. Lancet. 2009 Jul 18;374(9685):210-21. doi: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26. Lancet. 2009. PMID: 19560810 Clinical Trial.

2

Patient Perspectives on Intravenous Biologics for Rheumatologic Disease.

Grisanti L, Kwiatkowski A, Dyrda P, Field E, Grisanti J, Hatem J, Dehoratius RJ, Gaylis N. Grisanti L, et al. Among authors: gaylis n. Arthritis Care Res (Hoboken). 2019 Sep;71(9):1234-1242. doi: 10.1002/acr.23758. Epub 2019 Aug 7. Arthritis Care Res (Hoboken). 2019. PMID: 30221490

3

Proceedings from the 7th Annual International Society for Musculoskeletal Imaging in Rheumatology (ISEMIR) conference.

Troum OM, Pimienta OL, Schmidt WA, Ostergaard M, D'Agostino MA, Gaylis N, Arnold W, Ben-Artzi A, Ranganath V, Seraphine JL, Peterfy C. Troum OM, et al. Among authors: gaylis n. Semin Arthritis Rheum. 2015 Aug;45(1):115-21. doi: 10.1016/j.semarthrit.2015.02.011. Epub 2015 Mar 3. Semin Arthritis Rheum. 2015. PMID: 25908178 Review.

4

Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).

Blauvelt A, Leonardi CL, Gaylis N, Jauch-Lembach J, Balfour A, Lemke L, Hachaichi S, Brueckmann I, Festini T, Wiland P. Blauvelt A, et al. Among authors: gaylis n. BioDrugs. 2021 Mar;35(2):229-238. doi: 10.1007/s40259-021-00470-1. Epub 2021 Mar 2. BioDrugs. 2021. PMID: 33651341 Free PMC article. Clinical Trial.

5

Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study.

Wiland P, Jeka S, Dokoupilová E, Brandt-Jürgens J, Miranda Limón JM, Cantalejo Moreira M, Cabello RV, Jauch-Lembach J, Thakur A, Haliduola H, Brueckmann I, Gaylis NB. Wiland P, et al. Among authors: gaylis nb. BioDrugs. 2020 Dec;34(6):809-823. doi: 10.1007/s40259-020-00447-6. BioDrugs. 2020. PMID: 33119861 Free PMC article. Clinical Trial.

6

The value of magnetic resonance imaging in clinical practice.

Gaylis NB. Gaylis NB. J Clin Rheumatol. 2014 Jun;20(4):211-4. doi: 10.1097/RHU.0000000000000113. J Clin Rheumatol. 2014. PMID: 24847748 No abstract available.

7

Patient-reported outcome assessment of inflammatory arthritis patient experience with intravenously administered biologic therapy.

Gaylis NB, Sagliani J, Black S, Tang KL, DeHoratius R, Kafka WA, Parenti D. Gaylis NB, et al. Patient Prefer Adherence. 2017 Sep 12;11:1543-1553. doi: 10.2147/PPA.S136567. eCollection 2017. Patient Prefer Adherence. 2017. PMID: 28979103 Free PMC article.

8

Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome.

Gaylis NB, Ritter A, Kelly SA, Pourhassan NZ, Tiwary M, Sacha JB, Hansen SG, Recknor C, Yang OO. Gaylis NB, et al. Clin Infect Dis. 2022 Apr 22:ciac226. doi: 10.1093/cid/ciac226. Online ahead of print. Clin Infect Dis. 2022. PMID: 35452519

9

Proceedings from the 5th Annual International Society for Musculoskeletal Imaging in Rheumatology Annual Conference.

Conaghan PG, Ostergaard M, D'Agostino MA, Gaylis N, Arnold W, Olech E, Wells A, Peterfy C, Seraphine JL, Troum O. Conaghan PG, et al. Among authors: gaylis n. Semin Arthritis Rheum. 2013 Feb;42(4):433-46. doi: 10.1016/j.semarthrit.2012.10.003. Semin Arthritis Rheum. 2013. PMID: 23415135

10

Considering Immuno-autonomics in Stratifying Successful Treatment of Rheumatoid Arthritis with Tumor Necrosis Factor Inhibition: Comment on Cohen et al. Rheumatol Ther 2021 June 19.

Holman AJ, Keystone E, Choy E, Furst D, Taylor P, Gaylis N. Holman AJ, et al. Among authors: gaylis n. Rheumatol Ther. 2022 Feb;9(1):305-307. doi: 10.1007/s40744-021-00386-w. Epub 2021 Nov 10. Rheumatol Ther. 2022. PMID: 34757532 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results